Is Vigil Neuroscience Stock a Good Investment?
Vigil Neuroscience Investment Advice | VIGL |
- Examine Vigil Neuroscience's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Vigil Neuroscience's leadership team and their track record. Good management can help Vigil Neuroscience navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Vigil Neuroscience's business and its evolving consumer preferences.
- Compare Vigil Neuroscience's performance and market position to its competitors. Analyze how Vigil Neuroscience is positioned in terms of product offerings, innovation, and market share.
- Check if Vigil Neuroscience pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Vigil Neuroscience's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Vigil Neuroscience stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Vigil Neuroscience is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Vigil Neuroscience Stock
Researching Vigil Neuroscience's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 21.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 1.41. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vigil Neuroscience recorded a loss per share of 2.07. The entity had not issued any dividends in recent years.
To determine if Vigil Neuroscience is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vigil Neuroscience's research are outlined below:
| Vigil Neuroscience generated a negative expected return over the last 90 days | |
| Vigil Neuroscience has high historical volatility and very poor performance | |
| Vigil Neuroscience has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (82.64 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Vigil Neuroscience currently holds about 148.91 M in cash with (70.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.27, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vigil Neuroscience has a frail financial position based on the latest SEC disclosures | |
| Over 80.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Citadel Advisors LLC Adjusts Position in Vigil Neuroscience Inc |
Vigil Neuroscience Quarterly Cost Of Revenue |
|
Vigil Neuroscience uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vigil Neuroscience. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vigil Neuroscience's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Vigil Neuroscience's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Vigil Neuroscience's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -0.535 | -0.47 | 0.065 | 12 | ||
2022-11-10 | 2022-09-30 | -0.6 | -0.53 | 0.07 | 11 | ||
2022-08-08 | 2022-06-30 | -0.67 | -0.6 | 0.07 | 10 | ||
2023-03-21 | 2022-12-31 | -0.58 | -0.48 | 0.1 | 17 | ||
2022-01-10 | 2021-12-31 | -0.7833 | -8.28 | -7.4967 | 957 |
Know Vigil Neuroscience's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vigil Neuroscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vigil Neuroscience backward and forwards among themselves. Vigil Neuroscience's institutional investor refers to the entity that pools money to purchase Vigil Neuroscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rock Springs Capital Management Lp | 2024-06-30 | 472 K | Orbimed Advisors, Llc | 2024-06-30 | 448.9 K | Blackrock Inc | 2024-06-30 | 405 K | Goldman Sachs Group Inc | 2024-06-30 | 401.1 K | Ensign Peak Advisors Inc | 2024-06-30 | 395.1 K | Millennium Management Llc | 2024-06-30 | 334.8 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-06-30 | 289.5 K | Abrdn Plc | 2024-09-30 | 235 K | Woodline Partners Lp | 2024-06-30 | 206.6 K | Northpond Ventures, Llc | 2024-09-30 | 4.2 M | Artal Group S A | 2024-06-30 | 1.8 M |
Vigil Neuroscience's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 124.68 M.Market Cap |
|
Vigil Neuroscience's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.69) | (0.72) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (0.71) | (0.68) |
Determining Vigil Neuroscience's profitability involves analyzing its financial statements and using various financial metrics to determine if Vigil Neuroscience is a good buy. For example, gross profit margin measures Vigil Neuroscience's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vigil Neuroscience's profitability and make more informed investment decisions.
Evaluate Vigil Neuroscience's management efficiency
Vigil Neuroscience has return on total asset (ROA) of (0.3966) % which means that it has lost $0.3966 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7012) %, meaning that it created substantial loss on money invested by shareholders. Vigil Neuroscience's management efficiency ratios could be used to measure how well Vigil Neuroscience manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.62. The value of Return On Capital Employed is expected to slide to -0.72. At this time, Vigil Neuroscience's Net Tangible Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 19.9 M this year, although the value of Other Current Assets will most likely fall to about 2.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.00 | 3.15 | |
| Tangible Book Value Per Share | 3.00 | 3.15 | |
| Enterprise Value Over EBITDA | (1.05) | (1.10) | |
| Price Book Value Ratio | 1.13 | 1.18 | |
| Enterprise Value Multiple | (1.05) | (1.10) | |
| Price Fair Value | 1.13 | 1.18 | |
| Enterprise Value | 92.7 M | 155.3 M |
At Vigil Neuroscience, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 1.934 |
Basic technical analysis of Vigil Stock
As of the 22nd of November, Vigil Neuroscience has the Variance of 13.41, risk adjusted performance of (0.03), and Coefficient Of Variation of (2,180). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vigil Neuroscience, as well as the relationship between them. Please validate Vigil Neuroscience standard deviation and value at risk to decide if Vigil Neuroscience is priced more or less accurately, providing market reflects its prevalent price of 3.0 per share. Given that Vigil Neuroscience has information ratio of (0.07), we advise you to double-check Vigil Neuroscience's current market performance to make sure the company can sustain itself at a future point.Vigil Neuroscience's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vigil Neuroscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vigil Neuroscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vigil Neuroscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vigil Neuroscience's Outstanding Corporate Bonds
Vigil Neuroscience issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vigil Neuroscience uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vigil bonds can be classified according to their maturity, which is the date when Vigil Neuroscience has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Viking Cruises Ltd Corp BondUS92676XAD93 | View | |
| Viking Cruises Ltd Corp BondUS92676XAC11 | View | |
| US92676XAF42 Corp BondUS92676XAF42 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
Understand Vigil Neuroscience's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Vigil Neuroscience's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.20) | |||
| Mean Deviation | 2.68 | |||
| Coefficient Of Variation | (2,180) | |||
| Standard Deviation | 3.66 | |||
| Variance | 13.41 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.25) | |||
| Total Risk Alpha | (0.59) | |||
| Treynor Ratio | (0.21) | |||
| Maximum Drawdown | 19.63 | |||
| Value At Risk | (6.30) | |||
| Potential Upside | 5.29 | |||
| Skewness | 0.1917 | |||
| Kurtosis | 1.04 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.20) | |||
| Mean Deviation | 2.68 | |||
| Coefficient Of Variation | (2,180) | |||
| Standard Deviation | 3.66 | |||
| Variance | 13.41 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.25) | |||
| Total Risk Alpha | (0.59) | |||
| Treynor Ratio | (0.21) | |||
| Maximum Drawdown | 19.63 | |||
| Value At Risk | (6.30) | |||
| Potential Upside | 5.29 | |||
| Skewness | 0.1917 | |||
| Kurtosis | 1.04 |
Consider Vigil Neuroscience's intraday indicators
Vigil Neuroscience intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vigil Neuroscience stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Vigil Neuroscience Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 9th of October 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 12th of August 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Vigil Stock media impact
Far too much social signal, news, headlines, and media speculation about Vigil Neuroscience that are available to investors today. That information is available publicly through Vigil media outlets and privately through word of mouth or via Vigil internal channels. However, regardless of the origin, that massive amount of Vigil data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vigil Neuroscience news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vigil Neuroscience relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vigil Neuroscience's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vigil Neuroscience alpha.
Vigil Neuroscience Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Vigil Neuroscience can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Vigil Neuroscience Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Spyridon MD | Chief Officer | Profile | |
| Weeteck Yeo | Senior Operations | Profile | |
| Jessica PMP | Senior Management | Profile | |
| Mr DABT | Senior Development | Profile | |
| Christopher JD | General Secretary | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vigil Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vigil Neuroscience. If investors know Vigil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vigil Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.07) | Return On Assets (0.40) | Return On Equity (0.70) |
The market value of Vigil Neuroscience is measured differently than its book value, which is the value of Vigil that is recorded on the company's balance sheet. Investors also form their own opinion of Vigil Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Vigil Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vigil Neuroscience's market value can be influenced by many factors that don't directly affect Vigil Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Vigil Neuroscience's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Vigil Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vigil Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.